On December 8, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld, a monoclonal antibody combination of tixagevimab and cilgavimab.
Ask the Doctor: What is the difference between a partial response to testing and having undetectable MRD?
Ask the Doctor: What is the difference between a partial response to testing and having
LRF Scientific Leadership and Investment in Innovative Research Highlighted at 2021 American Society of Hematology Annual Meeting
LRF Scientific Advisory Board Members Joined by Current and Former Grantees at the 63rd ASH Annual Meeting & Exposition
U.S. Food and Drug Administration Approves Rituximab (RITUXAN) Plus Chemotherapy for Pediatric B-cell Lymphomas
Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).
Recommended questions lymphoma patients, survivors, and caregivers can ask their healthcare provider.
We welcome members of the press to contact our Communications team at firstname.lastname@example.org with any media-related questions or interview requests.